Anthrax – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Anthrax – Pipeline Review, H2 2017’, provides an overview of the Anthrax pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anthrax, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anthrax and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Anthrax

The report reviews pipeline therapeutics for Anthrax by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Anthrax therapeutics and enlists all their major and minor projects

The report assesses Anthrax therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Anthrax

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Anthrax

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Anthrax pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Altimmune Inc

Aphios Corp

Aradigm Corp

Companhia Industrial Produtora de Antibioticos SA

ContraFect Corp

Crestone Inc

Dynavax Technologies Corp

Emergent BioSolutions Inc

GlaxoSmithKline Plc

Green Cross Corp

Grifols SA

Hawaii Biotech Inc

iBio Inc

Merck & Co Inc

Microbiotix Inc

NanoBio Corp

PaxVax Inc

Pfenex Inc

Protein Potential LLC

ProThera Biologics Inc

Soligenix Inc

Syntiron LLC

Tetraphase Pharmaceuticals Inc

VLP Biotech Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Anthrax - Overview 8

Anthrax - Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Pipeline by Universities/Institutes 13

Products under Development by Companies 14

Products under Development by Universities/Institutes 17

Anthrax - Therapeutics Assessment 18

Assessment by Target 18

Assessment by Mechanism of Action 20

Assessment by Route of Administration 22

Assessment by Molecule Type 24

Anthrax - Companies Involved in Therapeutics Development 26

Altimmune Inc 26

Aphios Corp 26

Aradigm Corp 27

Companhia Industrial Produtora de Antibioticos SA 27

ContraFect Corp 28

Crestone Inc 28

Dynavax Technologies Corp 29

Emergent BioSolutions Inc 29

GlaxoSmithKline Plc 30

Green Cross Corp 30

Grifols SA 31

Hawaii Biotech Inc 31

iBio Inc 32

Merck & Co Inc 32

Microbiotix Inc 33

NanoBio Corp 33

PaxVax Inc 34

Pfenex Inc 34

Protein Potential LLC 35

ProThera Biologics Inc 35

Soligenix Inc 36

Syntiron LLC 36

Tetraphase Pharmaceuticals Inc 37

VLP Biotech Inc 37

Anthrax - Drug Profiles 38

anthrax (virus like particles) vaccine - Drug Profile 38

anthrax + plague vaccine - Drug Profile 39

anthrax vaccine - Drug Profile 40

anthrax vaccine - Drug Profile 42

anthrax vaccine - Drug Profile 43

anthrax vaccine - Drug Profile 44

anthrax vaccine - Drug Profile 45

anthrax vaccine - Drug Profile 46

Antisense RNAi Oligonucleotide to Inhibit ANTXR1 and ANTXR2 for Anthrax - Drug Profile 47

ARD-3100 - Drug Profile 48

AV-7909 - Drug Profile 52

BDM-I - Drug Profile 55

CF-306 - Drug Profile 58

CF-307 - Drug Profile 59

CF-308 - Drug Profile 60

ciprofloxacin hydrochloride - Drug Profile 61

CPN-1311 - Drug Profile 62

DPX-Anthrax - Drug Profile 63

DV-230 - Drug Profile 66

epimerox - Drug Profile 67

EV-035 - Drug Profile 68

GC-1109 - Drug Profile 70

gepotidacin mesylate - Drug Profile 71

GREANX - Drug Profile 74

KKL-35 - Drug Profile 75

Marinus - Drug Profile 76

Monoclonal Antibody for Anthrax - Drug Profile 77

Monoclonal Antibody for Anthrax - Drug Profile 78

Monoclonal Antibody to Inhibit Anthrax Protective Antigen for Anthrax - Drug Profile 79

Nasoshield - Drug Profile 80

PBI-220 - Drug Profile 82

Peptides to Disrupt Cell Membrane for Infectious Diseases - Drug Profile 84

Protein to Inhibit Furin for Anthrax Intoxication and Sepsis - Drug Profile 85

Px-563L - Drug Profile 87

Px-563L Second Generation - Drug Profile 89

raxibacumab - Drug Profile 90

Recombinant Proteins for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections and Anthrax - Drug Profile 91

RiVax + SGX-204 - Drug Profile 92

rPA-01 - Drug Profile 93

RPA-563 - Drug Profile 94

Small Molecules for Bacterial Infections, Skin Infections and Bone Disorders - Drug Profile 95

Small Molecules to Inhibit Anthrax Lethal Factor Toxin for Anthrax - Drug Profile 96

Small Molecules to Inhibit Lethal Factor for Anthrax - Drug Profile 97

Small Molecules to Inhibit Lethal Factor for Anthrax and Cystic Fibrosis - Drug Profile 99

Small Molecules to Inhibit PolC for Gram-Positive Bacterial Infections - Drug Profile 100

solithromycin - Drug Profile 101

SparVax - Drug Profile 115

TP-271 - Drug Profile 120

Anthrax - Dormant Projects 123

Anthrax - Discontinued Products 126

Anthrax - Product Development Milestones 127

Featured News & Press Releases 127

Appendix 138

Methodology 138

Coverage 138

Secondary Research 138

Primary Research 138

Expert Panel Validation 138

Contact Us 138

Disclaimer 139

List of Tables

List of Tables

Number of Products under Development for Anthrax, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Anthrax – Pipeline by Altimmune Inc, H2 2017

Anthrax – Pipeline by Aphios Corp, H2 2017

Anthrax – Pipeline by Aradigm Corp, H2 2017

Anthrax – Pipeline by Companhia Industrial Produtora de Antibioticos SA, H2 2017

Anthrax – Pipeline by ContraFect Corp, H2 2017

Anthrax – Pipeline by Crestone Inc, H2 2017

Anthrax – Pipeline by Dynavax Technologies Corp, H2 2017

Anthrax – Pipeline by Emergent BioSolutions Inc, H2 2017

Anthrax – Pipeline by GlaxoSmithKline Plc, H2 2017

Anthrax – Pipeline by Green Cross Corp, H2 2017

Anthrax – Pipeline by Grifols SA, H2 2017

Anthrax – Pipeline by Hawaii Biotech Inc, H2 2017

Anthrax – Pipeline by iBio Inc, H2 2017

Anthrax – Pipeline by Merck & Co Inc, H2 2017

Anthrax – Pipeline by Microbiotix Inc, H2 2017

Anthrax – Pipeline by NanoBio Corp, H2 2017

Anthrax – Pipeline by PaxVax Inc, H2 2017

Anthrax – Pipeline by Pfenex Inc, H2 2017

Anthrax – Pipeline by Protein Potential LLC, H2 2017

Anthrax – Pipeline by ProThera Biologics Inc, H2 2017

Anthrax – Pipeline by Soligenix Inc, H2 2017

Anthrax – Pipeline by Syntiron LLC, H2 2017

Anthrax – Pipeline by Tetraphase Pharmaceuticals Inc, H2 2017

Anthrax – Pipeline by VLP Biotech Inc, H2 2017

Anthrax – Dormant Projects, H2 2017

Anthrax – Dormant Projects, H2 2017 (Contd..1), H2 2017

Anthrax – Dormant Projects, H2 2017 (Contd..2), H2 2017

Anthrax – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Anthrax, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports